The authors also found that treatment with ibrutinib disrupts the interaction between tumor-associated macrophages (TAM) and tumor cells in the bone marrow, inhibits the secretion of CXCL13, and decreases the chemoattraction of CLL cells [43]. This evidence concerns the gene CXCL13 and neoplasm.